cabozantinib,nivolumab
exelixis,bms
['9er', 'nivo']
dr. cristina suarez presented port-hoc analysis of cm9er evaluating the depth of response and long term benefit. cabo-nivo more than doubles the chances of &gt;60% tumor reduction (38 versus 17%). 14% cr rate in favor of cabo-nivo. #asco22 
Medical oncologist at @BPorgbr. Former fellow of GU oncology @DanaFarber @Harvard @MOCbrasil. #GUcancer